Will Dendreon Corporation (DNDN) Ever Make Money?

Page 2 of 2

Dendreon did manage to get one potential problem behind it, settling a securities class action lawsuit for $40 million. With 95% of that coming from insurance carriers, Dendreon Corporation (NASDAQ:DNDN) won’t suffer a major cash hit, which is an important victory given the company’s persistent losses and consequent drain on cash.

In Dendreon Corporation (NASDAQ:DNDN)’s quarterly report, watch for news on where Provenge stands in the company’s attempt to get EU approval for the drug. If Europe comes on board, then it might finally provide the sales boost that investors have waited years to see.

The article Will Dendreon Ever Make Money? originally appeared on Fool.com and is written by Dan Caplinger.

Fool contributor Dan Caplinger has no position in any stocks mentioned. You can follow him on Twitter @DanCaplinger. The Motley Fool recommends Johnson & Johnson (NYSE:JNJ). The Motley Fool owns shares of Dendreon and Johnson & Johnson (NYSE:JNJ).

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Page 2 of 2